This Weight-Loss Drug Stock Could Gain 200%, Challenge Novo Nordisk, Eli Lilly. - Barron's

1. Novo Nordisk and Eli Lilly lead in weight-loss drugs market. 2. Viking Therapeutics initiates late-stage trials for injectable weight-loss treatment. 3. Analysts set high price targets for Viking, indicating strong market expectations. 4. Viking also seen as a potential acquisition target by larger companies. 5. Investors closely monitoring development of competitors’ obesity treatments.